MediClin reported that its 2025 top line rose 4.8% year-over-year to EUR 784.50 million, a figure that marginally exceeded a consensus estimate of EUR 782.40 million from one analyst. The company said inpatient volumes increased by 1% over the period.
On the profitability front, group EBIT climbed 3.5% from the prior year to EUR 55.40 million. Management attributed the revenue and operating profit gains to improvements in the post-acute segment, which benefited from higher earnings and the implementation of strategic measures designed to bolster performance.
COO Thomas Piefke highlighted that stable occupancy rates at MediClin facilities supported operational results. The company contrasted that stable utilisation in post-acute services with a contraction in its acute care segment. The decline in acute care revenue was primarily caused by the sale of the former MEDICLIN Heart Centre Coswig, which removed that asset from the group’s revenue base.
Looking ahead, MediClin set out targets for 2026 that foresee continued top-line expansion and a wider range for operating profit. The company expects revenue to grow between 3.5% and 6.5% year-on-year. For group EBIT, management provided guidance in a range from EUR 57.0 million to EUR 72.0 million. The board noted that the outlook rests on solid operational capacity utilisation across the group.
The year-end results show a company with modest growth and a focused operational narrative: post-acute services drove the improvement, occupancy levels remained supportive, and a discrete asset sale weighed on the acute care line. The 2026 guidance reflects management’s confidence in capacity utilisation while also conveying a degree of uncertainty in the breadth of the EBIT range.
Summary
MediClin recorded a 4.8% increase in 2025 revenue to EUR 784.50 million, a small beat on one analyst consensus. Group EBIT rose 3.5% to EUR 55.40 million. Growth was led by the post-acute segment, while acute care revenue fell following the sale of the MEDICLIN Heart Centre Coswig. For 2026 the company expects revenue growth of 3.5% to 6.5% and group EBIT of EUR 57.0 million to EUR 72.0 million, citing solid capacity utilisation.
Key points
- Revenue rose 4.8% to EUR 784.50 million in 2025, just above a single-analyst consensus of EUR 782.40 million.
- Group EBIT increased 3.5% to EUR 55.40 million, with the post-acute segment contributing the primary uplift.
- Revenue in the acute care segment declined due to the sale of the former MEDICLIN Heart Centre Coswig; management expects 2026 revenue growth of 3.5% to 6.5% and group EBIT between EUR 57.0 million and EUR 72.0 million.
Risks and uncertainties
- The divestment of the MEDICLIN Heart Centre Coswig reduced acute care revenue, illustrating how asset sales can materially affect segment results and comparability.
- The company’s 2026 guidance spans a wide EBIT range, signalling uncertainty in near-term profitability outcomes despite positive capacity utilisation assumptions.
- The slight nature of the revenue beat relative to a single analyst consensus suggests sensitivity to estimates and the potential for variation in market expectations.